Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Emina Suljovic Hadzimesic"'
Autor:
Erna Islamagic, Sabira Kurtovic, Mirza Kozaric, Lejla Mehinovic, Azra Hasic, Amina Kurtovic-Kozaric, Emina Suljovic Hadzimesic
Publikováno v:
Clinical lymphoma, myelomaleukemia. 17(4)
Introduction Generics of imatinib mesylate, the first tyrosine kinase inhibitor targeting the BCR-ABL1 fusion protein, have recently been approved in many countries as the alternative, low-cost forms for the treatment of patients with chronic myeloid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5f549f6e2276dff58c61d9219b0a2c4
https://pubmed.ncbi.nlm.nih.gov/28283298
https://pubmed.ncbi.nlm.nih.gov/28283298
Publikováno v:
Medical Archives
Introduction: Non Hodgkin lymphoma-Diffuse large B cell lymphoma (DLBC) is composed of more varieties of one disease. Analysis and understanding of a wide range of characteristics of the disease, which include: clinical, immunohistochemical, cytogene
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33cc6c769a40e3ac1108b2feeddcfd0d
https://pubmed.ncbi.nlm.nih.gov/27994293
https://pubmed.ncbi.nlm.nih.gov/27994293
Autor:
Emina Suljovic Hadzimesic, Azra Hasic, Jerald P. Radich, Sabira Kurtovic, Erna Islamagic, Amina Kurtovic Kozaric
Publikováno v:
Blood. 128:5451-5451
Introduction Imatinib mesylate (Glivec, Novartis) is the first tyrosine kinase inhibitor (TKI) targeting the BCR-ABL1 fusion protein responsible for the pathogenesis of chronic myeloid leukemia (CML). Low cost generic alternatives to imatinib are an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::660b2d50e22e5533eb9af2394771716e
https://doi.org/10.1182/blood.v128.22.5451.5451
https://doi.org/10.1182/blood.v128.22.5451.5451